DGAP-News: STRATEC Biomedical AG / Key word(s): Takeover/Acquisition
STRATEC signed an agreement to acquire the BioSciences business of Sony DADC
08.06.2016 / 14:37
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
STRATEC signed an agreement to acquire the BioSciences business of Sony
DADC
- Significantly expands product portfolio to include smart consumables
- Diversifies overall customer structure and extends value chain
- Complementary service portfolio adds recurring revenue stream
- Revenue expectation of around EUR 17 million for current financial year
Birkenfeld, June 8, 2016
STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard,
TecDAX), today signed an agreement with Sony DADC Austria AG ("Sony DADC"),
based in Anif/Salzburg, Austria, to acquire all of the shares of its
BioSciences business, Sony DADC BioSciences GmbH ("Sony DADC BioSciences"),
which is a wholly-owned subsidiary of Sony DADC. The acquisition is
expected to be completed by the end of the third quarter 2016.
Building on Sony DADC's experience in high-precision optical disc
manufacturing, Sony DADC induced 6 years ago the formation of its
BioSciences business. Sony DADC BioSciences is a leading global OEM
supplier of smart consumables for diagnostics, life sciences and medical
technology applications. The company has a unique combination of skills and
technologies including nano- and microstructuring, coating technologies,
polymer sciences, and automated assembly. Sony DADC BioSciences has a
certified production facility and a global logistics network and covers the
entire value chain, from development and design via production and quality
assurance through to logistics. The company meets all regulatory
requirements in the relevant target markets. Its customers include global
players in highly regulated markets as well as innovative start-ups.
Furthermore, the company has numerous partnerships with universities and
research institutes. Alongside its headquarters in Anif near Salzburg in
Austria, the company has sales offices in both Asia and America.
In the current financial year, ending on March 31, 2017, the company is
expected to generate sales of around EUR 17 million with slightly positive
earnings contributing to STRATECs EBIT. Based on current planning, the
management teams expect a continuously growing EBIT margin to reach the
current group's EBIT margin by 2020. Consolidation within the STRATEC group
is expected after closing. The company currently has approximately 120
employees. The company valuation set in the sale and purchase agreement
amounts over EUR 30 million.
Comments Marcus Wolfinger, CEO of STRATEC: "With the acquisition of Sony
DADC BioSciences, we are expanding the STRATEC Group to include an
innovation leader in a very attractive growth market. This combination of
an experienced, highly qualified team with innovative products and
established customer relationships is an ideal addition to STRATEC's
product portfolio. After closing this acquisition we will be able to offer
solutions to our customers from a significantly broader technology
spectrum, one that encompasses entirely new solutions in the field of smart
consumables. We have been co-operating with the team in Anif in several
major development projects for several years now and are impressed by their
professionalism and innovative power. We believe that pooling our strengths
this way will help us to access new growth opportunities for the STRATEC
Group while also diversifying cluster risks."
Dr. Chris Mauracher, Managing Director of Sony DADC BioSciences added: "The
two business models are very similar in terms of their partnership-driven
approach, transferring development activities into continuous cash flow
generating production. Given our different positions within the same value
chain, we thus complement each other ideally. This combination now enables
us to offer complete solutions comprising instrumentation, consumables and
smart consumables from one single source. From a customer perspective, that
reduces the number of contact partners and thus the complexity and process
risk. We are optimistic that this will soon also be reflected in an even
better offer to order ratio with our partners."
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, as system solutions to
laboratories, blood banks and research institutes around the world. The
company develops its products on the basis of its own patented
technologies.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.
About Sony DADC BioSciences GmbH
Building on Sony DADC's experience in high-precision optical disc
manufacturing, Sony DADC BioSciences partners with Life Sciences and
Diagnostics companies enabling the industrial manufacturing of smart
polymer parts.
About Sony DADC
Sony DADC is a leading disc and digital solution provider for the
entertainment, education and information industries, offering world-class
optical media replication services, digital and physical supply chain
solutions and software services. The company's network consists of service
offices, optical media production, distribution and digital facilities
worldwide.
Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com
Sony DADC International
Karin Ploner, Communications
Sonystr. 20, A-5081 Anif/Salzburg
Austria
Tel: +43 6246 880 8398
karin.ploner@sonydadc.com
www.sonydadc.com
---------------------------------------------------------------------------
08.06.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec.com
Internet: www.stratec.com
ISIN: DE000STRA555
WKN: STRA55
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX
End of News DGAP News Service
---------------------------------------------------------------------------
470107 08.06.2016
DGAP-News: STRATEC signed an agreement to acquire the BioSciences business of Sony DADC
| Source: EQS Group AG